论文信息 - Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization. Methods: We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the pathology of invasive breast, ovarian, and contralateral breast cancers. Results: There was strong evidence that the proportion of estrogen receptor (ER)-negative breast tumors decreased with age at diagnosis among BRCA1 (P-trend = 1.2 × 10−5), but increased with age at diagnosis among BRCA2, carriers (P-trend = 6.8 × 10−6). The proportion of triple-negative tumors decreased with age at diagnosis in BRCA1 carriers but increased with age at diagnosis of BRCA2 carriers. In both BRCA1 and BRCA2 carriers, ER-negative tumors were of higher histologic grade than ER-positive tumors (grade 3 vs. grade 1; P = 1.2 × 10−13 for BRCA1 and P = 0.001 for BRCA2). ER and progesterone receptor (PR) expression were independently associated with mutation carrier status [ER-positive odds ratio (OR) for BRCA2 = 9.4, 95% CI: 7.0–12.6 and PR-positive OR = 1.7, 95% CI: 1.3–2.3, under joint analysis]. Lobular tumors were more likely to be BRCA2-related (OR for BRCA2 = 3.3, 95% CI: 2.4–4.4; P = 4.4 × 10−14), and medullary tumors BRCA1-related (OR for BRCA2 = 0.25, 95% CI: 0.18–0.35; P = 2.3 × 10−15). ER-status of the first breast cancer was predictive of ER-status of asynchronous contralateral breast cancer (P = 0.0004 for BRCA1; P = 0.002 for BRCA2). There were no significant differences in ovarian cancer morphology between BRCA1 and BRCA2 carriers (serous: 67%; mucinous: 1%; endometrioid: 12%; clear-cell: 2%). Conclusions/Impact: Pathologic characteristics of BRCA1 and BRCA2 tumors may be useful for improving risk-prediction algorithms and informing clinical strategies for screening and prophylaxis. Cancer Epidemiol Biomarkers Prev; 21(1); 134–47. ©2011 AACR.

[1] Mads Thomassen,et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 , 2011, Breast Cancer Research.

[2] Patrick Neven,et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.

[3] M. Southey,et al. Morphological predictors of BRCA1 germline mutations in young women with breast cancer , 2011, British Journal of Cancer.

[4] A. Antoniou,et al. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5] S. Gautam,et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers , 2010, Breast Cancer Research.

[6] A. Vargas,et al. The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers , 2010, Familial Cancer.

[7] T. Rebbeck,et al. Incorporating tumour pathology information into breast cancer risk prediction algorithms , 2010, Breast Cancer Research.

[8] M. García-Closas,et al. Molecular Pathology in Epidemiologic Studies: A Primer on Key Considerations , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[9] S. Lakhani,et al. Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic? , 2010, Breast Cancer Research.

[10] D. Sgroi,et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features , 2010, Breast Cancer Research.

[11] E A Jones,et al. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing , 2009, Journal of Medical Genetics.

[12] Christopher I Amos,et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13] J. Benítez,et al. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes , 2008, Oncogene.

[14] Peter Kraft,et al. Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.

[15] G. Parmigiani,et al. Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction , 2008, Breast Cancer Research.

[16] Tara L. Naylor,et al. Estrogen Receptor Status Could Modulate the Genomic Pattern in Familial and Sporadic Breast Cancer , 2007, Clinical Cancer Research.

[17] Ian O Ellis,et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18] Georgia Chenevix-Trench,et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.

[19] A. Whittemore,et al. BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays , 2007, The American journal of surgical pathology.

[20] Olga Anczuków,et al. The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon , 2006, Human mutation.

[21] Julian Peto,et al. Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[22] O. Olopade,et al. A Comparison of Bilateral Breast Cancers in BRCA Carriers , 2005, Cancer Epidemiology Biomarkers & Prevention.

[23] H. Nevanlinna,et al. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families , 2005, Breast Cancer Research.

[24] J. Cigudosa,et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers , 2005, Breast Cancer Research and Treatment.

[25] I. Ellis,et al. Are Medullary Breast Cancers an Indication for BRCA1 Mutation Screening? A Mutation Analysis of 42 Cases of Medullary Breast Cancer , 2004, Breast Cancer Research and Treatment.

[26] Norman Wolmark,et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. , 2004, Journal of the National Cancer Institute.

[27] J. Klijn,et al. Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[28] O. Olopade,et al. Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.

[29] Nilanjan Chatterjee,et al. Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database , 2002, Breast Cancer Research and Treatment.

[30] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31] D. Stoppa-Lyonnet,et al. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. , 2002, Human molecular genetics.

[32] I. Jacobs,et al. Histopathologic Features of Genetically Determined Ovarian Cancer , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[33] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34] D. Easton,et al. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.

[35] K. Phillips. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36] M. Vinceti,et al. Comparison between genotype and phenotype identifies a high‐risk population carrying BRCA1 mutations , 2000, Genes, chromosomes & cancer.

[37] Daniel Birnbaum,et al. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes , 1999, Cancer.

[38] G. Giles,et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. , 1999, Cancer research.

[39] G. Giles,et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations , 1998, Cancer.

[40] M. Stratton,et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[41] M. Fernö,et al. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes , 1998, Cancer.

[42] D. Birnbaum,et al. Mutations at BRCA1: the medullary breast carcinoma revisited. , 1998, Cancer research.

[43] G M Lenoir,et al. A BRCA1 nonsense mutation causes exon skipping. , 1998, American journal of human genetics.

[44] M N Pollak,et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women , 1997, Cancer.

[45] Å. Borg,et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. , 1997, European journal of cancer.

[46] S. Seal,et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene , 1997, Nature Genetics.

[47] M. Morgan,et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.